Scholarlink

<p>Cerebral vasospasm (CV) is a major complication following aneurysmal subarachnoid hemorrhage (aSAH), significantly contributing to morbidity and mortality. Nicardipine Prolonged-Release Implants (NPRI) offer targeted, localized drug delivery to prevent CV. This meta-analysis evaluated NPRI’s efficacy and safety in reducing CV, mortality, and adverse events in patients with aSAH undergoing aneurysm repair.&#xa0;A systematic review and meta-analysis followed PRISMA guidelines. We searched PubMed, Embase, and Cochrane (inception–November 2024). Included RCTs compared NPRI plus standard care vs. standard care alone. Outcomes: CV, mortality, and adverse events. A random-effects model calculated risk ratios (RR) with 95% confidence intervals (CI). Heterogeneity was assessed via I². Registered in PROSPERO (CRD42024629347).&#xa0;From 214 identified records, three RCTs comprising 84 patients (NPRI group: 45; control group: 39) met inclusion criteria. NPRI significantly reduced CV incidence (RR, 0.24 [95% CI, 0.09–0.60]; P = .002) with low heterogeneity (I² = 37%). Mortality was also significantly reduced in the NPRI group (RR, 0.18 [95% CI, 0.03–0.95]; P = .044; I² = 0%). Adverse events were less frequent in the NPRI group (RR, 0.42 [95% CI, 0.18–0.97]; P = .043; I² = 0%).&#xa0;This meta-analysis provides preliminary evidence supporting NPRI to reduce CV, mortality, and adverse events in aSAH. Despite the small number of included studies, low heterogeneity and significant effect sizes suggest NPRI as a promising intervention. Larger-scale RCTs with extended follow-up are required to validate these findings and define NPRI’s role in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of nicardipine prolonged-release implants in patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2025年10月24日

查看全文
  • Ocílio Ribeiro Gonçalves,
  • Luís O. S. Nogueira,
  • Mariana Letícia Bastos de Maximiano,
  • Lucas Cael Azevedo Ramos Bendaham,
  • Victor Arthur Ohannesian,
  • Claudio Lucca Lima Furtado,
  • Kenzo Ogasawara Donato,
  • Lídia Santos Oliveira,
  • Milene Vitória Sampaio Sobral,
  • Sofia Daher Pimentel,
  • Márcio Yuri,
  • Gustavo Sousa Noleto,
  • David Langer,
  • Christian Ferreira,
  • Yafell Serule,
  • Ahmet Gunkan,
  • David Gordon

摘要

Cerebral vasospasm (CV) is a major complication following aneurysmal subarachnoid hemorrhage (aSAH), significantly contributing to morbidity and mortality. Nicardipine Prolonged-Release Implants (NPRI) offer targeted, localized drug delivery to prevent CV. This meta-analysis evaluated NPRI’s efficacy and safety in reducing CV, mortality, and adverse events in patients with aSAH undergoing aneurysm repair. A systematic review and meta-analysis followed PRISMA guidelines. We searched PubMed, Embase, and Cochrane (inception–November 2024). Included RCTs compared NPRI plus standard care vs. standard care alone. Outcomes: CV, mortality, and adverse events. A random-effects model calculated risk ratios (RR) with 95% confidence intervals (CI). Heterogeneity was assessed via I². Registered in PROSPERO (CRD42024629347). From 214 identified records, three RCTs comprising 84 patients (NPRI group: 45; control group: 39) met inclusion criteria. NPRI significantly reduced CV incidence (RR, 0.24 [95% CI, 0.09–0.60]; P = .002) with low heterogeneity (I² = 37%). Mortality was also significantly reduced in the NPRI group (RR, 0.18 [95% CI, 0.03–0.95]; P = .044; I² = 0%). Adverse events were less frequent in the NPRI group (RR, 0.42 [95% CI, 0.18–0.97]; P = .043; I² = 0%). This meta-analysis provides preliminary evidence supporting NPRI to reduce CV, mortality, and adverse events in aSAH. Despite the small number of included studies, low heterogeneity and significant effect sizes suggest NPRI as a promising intervention. Larger-scale RCTs with extended follow-up are required to validate these findings and define NPRI’s role in clinical practice.